Avantor, Inc. · AVTR · FY2026 Q3 · Calendar Q4 2026
Avantor reports stronger growth and raises 2026 outlook
Avantor's Q3 results support a constructive operating trajectory: organic growth returned, VWR accelerated, BMP improved and management raised its outlook. The thesis still depends on sustaining margin expansion while navigating inflation, mix, Europe and BMP order timing.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about AVTR FY2026 Q3
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with the prior quarter, Avantor reported stronger organic growth, with VWR accelerating and BMP returning to positive organic growth. Management also highlighted broader AI and digital-tool adoption, further deleveraging and raised full-year guidance.
Guidance delta
Management raised full-year 2026 organic revenue, adjusted EPS and free-cash-flow guidance, building on the prior quarter's raised outlook.
Key takeaways
- Q3 revenue was $1.698 billion, with 5.2% organic growth.
- VWR accelerated to 5.8% organic growth, while BMP returned to positive organic growth.
- The Revival program, pricing recovery and operational improvements supported momentum.
- Free cash flow and deleveraging remained priorities as net leverage reached 3.1x.
- Management is expanding AI, e-commerce and digital-manufacturing capabilities.
Management priorities
- Execute the Revival program
- Expand AI tools and e-commerce capabilities
- Improve manufacturing, supply-chain and S&OP processes
- Continue deleveraging toward adjusted net leverage below 3x
- Use the December 8 Investor Day to discuss the long-term financial framework
Follow AVTR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Nov 16, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Stifel | Hold | Hold | Maintain | Oct 29, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 29, 2026 |
| Barclays | Underweight | Underweight | Maintain | Oct 29, 2026 |
| Baird | Outperform | Outperform | Maintain | Oct 29, 2026 |
| TD Cowen | Hold | Hold | Maintain | Oct 13, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 13, 2026 |
| UBS | Neutral | Neutral | Maintain | Sep 9, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 30, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 8, 2026 |
| Jefferies | Underperform | Hold | Downgrade | Dec 17, 2025 |
| JP Morgan | Neutral | Overweight | Downgrade | Oct 30, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Oct 16, 2025 |
| Goldman Sachs | Neutral | Buy | Downgrade | Apr 29, 2025 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 18, 2024 |
| William Blair | Market Perform | Outperform | Downgrade | Jul 31, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Jul 31, 2023 |
| B of A Securities | Buy | Buy | Maintain | Jul 31, 2023 |
| Keybanc | Overweight | Overweight | Maintain | Sep 15, 2022 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Sep 14, 2022 |
| Cleveland Research | Neutral | Buy | Downgrade | Sep 9, 2022 |
| Piper Sandler | Overweight | Neutral | Upgrade | Aug 2, 2021 |
| Stifel Nicolaus | Hold | Hold | Maintain | Nov 15, 2019 |
| Janney Capital | Buy | Buy | Maintain | Jun 14, 2019 |
| Piper Jaffray | Neutral | Neutral | Maintain | Jun 11, 2019 |
Named analyst price targets
Upside is calculated against the persisted previous close $15.54. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Deutsche Bank | Analyst unavailable | $17 | $16.46 | +9.4% | Oct 29, 2026 |
| Robert W. Baird | Analyst unavailable | $18 | $16.69 | +15.8% | Oct 29, 2026 |
| Barclays | Analyst unavailable | $16 | $16.69 | +3.0% | Oct 29, 2026 |
| Evercore ISI | Analyst unavailable | $17 | $16.69 | +9.4% | Oct 28, 2026 |
| RBC Capital | Dan Leonard | $17 | $16.69 | +9.4% | Oct 28, 2026 |
| UBS | Doug Schenkel | $16 | $15.25 | +3.0% | Sep 9, 2026 |
| Morgan Stanley | Analyst unavailable | $14 | $13.66 | -9.9% | Jul 30, 2026 |
| RBC Capital | Dan Leonard | $14 | $13.98 | -9.9% | Jul 30, 2026 |
| Deutsche Bank | Analyst unavailable | $13 | $14.06 | -16.3% | Jul 30, 2026 |
| Jefferies | Analyst unavailable | $13 | $14.38 | -16.3% | Jul 29, 2026 |
| Evercore ISI | Analyst unavailable | $10.5 | $10.4 | -32.4% | Jul 6, 2026 |
| Bernstein | Analyst unavailable | $10.5 | $10.08 | -32.4% | Jun 26, 2026 |
| UBS | Analyst unavailable | $8 | $9.43 | -48.5% | Jun 24, 2026 |
| Wolfe Research | Analyst unavailable | $7 | $9.19 | -55.0% | Jun 1, 2026 |
| RBC Capital | Analyst unavailable | $9 | $7.94 | -42.1% | May 14, 2026 |
| Barclays | Analyst unavailable | $7 | $8.18 | -55.0% | Apr 14, 2026 |
| Morgan Stanley | Analyst unavailable | $10 | $9.38 | -35.6% | Feb 13, 2026 |
| UBS | Dan Leonard | $10.5 | $9.34 | -32.4% | Feb 12, 2026 |
| Stifel Nicolaus | Analyst unavailable | $10 | $9.24 | -35.6% | Feb 12, 2026 |
| Jefferies | Tycho Peterson | $8 | $9.24 | -48.5% | Feb 12, 2026 |
| Barclays | Analyst unavailable | $9 | $9.64 | -42.1% | Feb 12, 2026 |
| Robert W. Baird | Analyst unavailable | $11 | $9.64 | -29.2% | Feb 12, 2026 |
| Evercore ISI | Vijay Kumar | $10 | $9.32 | -35.6% | Feb 11, 2026 |
| Evercore ISI | Analyst unavailable | $12 | $11.46 | -22.8% | Jan 5, 2026 |
| Jefferies | Tycho Peterson | $9 | $11.2 | -42.1% | Dec 17, 2025 |
| Barclays | Luke Sergott | $12 | $11.58 | -22.8% | Oct 30, 2025 |
| UBS | Analyst unavailable | $12 | $11.58 | -22.8% | Oct 30, 2025 |
| Barclays | Luke Sergott | $15 | $13.67 | -3.5% | Oct 2, 2025 |
| Stifel Nicolaus | Analyst unavailable | $12 | $11.3 | -22.8% | Aug 4, 2025 |
| Raymond James | Analyst unavailable | $14 | $11.3 | -9.9% | Aug 4, 2025 |
| Robert W. Baird | Analyst unavailable | $17 | $12.49 | +9.4% | Apr 28, 2025 |
| Morgan Stanley | Tejas Savant | $15 | $12.93 | -3.5% | Apr 28, 2025 |
| Barclays | Luke Sergott | $26 | $21.87 | +67.3% | Feb 3, 2025 |
| Bernstein | Eve Burstein | $24.5 | $21.66 | +57.7% | Jan 10, 2025 |
| Evercore ISI | Vijay Kumar | $26 | $21.2 | +67.3% | Jan 2, 2025 |
| Robert W. Baird | Catherine Schulte | $26 | $22.56 | +67.3% | Oct 28, 2024 |
| Morgan Stanley | Tejas Savant | $28 | $24.4 | +80.2% | Oct 21, 2024 |
| Robert W. Baird | Catherine Schulte | $27 | $26.02 | +73.7% | Jul 29, 2024 |
| Evercore ISI | Vijay Kumar | $27.5 | $25.6 | +77.0% | Jul 26, 2024 |
| Evercore ISI | Vijay Kumar | $27 | $20.77 | +73.7% | Jul 2, 2024 |
| Jefferies | Tycho Peterson | $28 | $24.08 | +80.2% | Jun 3, 2024 |
| Deutsche Bank | Justin Bowers | $25 | $24.38 | +60.9% | Apr 18, 2024 |
| Raymond James | Andrew Cooper | $30 | $23.05 | +93.1% | Feb 5, 2023 |
| Raymond James | Andrew Cooper | $36 | $28.34 | +131.7% | Aug 9, 2022 |
| Robert W. Baird | Catherine Schulte | $34 | $28.34 | +118.8% | Aug 8, 2022 |
| Barclays | Luke Sergott | $33 | $28.67 | +112.4% | Aug 4, 2022 |
| Wells Fargo | Analyst unavailable | $33 | $29.95 | +112.4% | Apr 25, 2022 |
| Stifel Nicolaus | Daniel Arias | $46 | $42.33 | +196.0% | Sep 10, 2021 |
| Credit Suisse | Katie Tryhane | $50 | $42.33 | +221.8% | Sep 10, 2021 |
| Guggenheim | Sandy Draper | $45 | $37.6 | +189.6% | Aug 2, 2021 |
| Morgan Stanley | Tejas Savant | $44 | $37.6 | +183.1% | Aug 2, 2021 |
| Goldman Sachs | Matthew Sykes | $40 | $31.3 | +157.4% | Jun 4, 2021 |
Track every rating change on AVTR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAvantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample…
Historical context
All AVTR earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ASND Ascendis Pharma A/S | FY2026 Q3 · Calendar Q4 2026 | +38.7% | +3.0% | Ascendis Q3 growth broadens the story, while execution risks remain |
| ALC Alcon Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | -2.3% | Alcon holds FY outlook as new launches meet IOL competition |
| TGTX TG Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | -2.6% | +5.9% | TG Therapeutics raises 2026 revenue outlook as BRIUMVI momentum continues |
| ROIV Roivant Sciences Ltd. | FY2026 Q2 · Calendar Q4 2026 | +33.8% | +4.6% | Roivant’s Q2: LISRAYA launch and pipeline data broaden the growth case |
Latest beats and misses
Who reports nextBeat on EPS
- NBISFY2026 Q3 · November 12, 2026+141.5% EPS-16.8% move
- AMATFY2026 Q4 · November 12, 2026+2.5% EPS-3.6% move
- CSCOFY2027 Q1 · November 12, 2026+5.3% EPS+1.2% move
- ASNDFY2026 Q3 · November 12, 2026+38.7% EPS+3.0% move
- TTEKFY2026 Q4 · November 11, 2026+4.6% EPS+4.8% move
- CTA-PAFY2026 Q3 · July 31, 2026+232.7% EPS— move
Missed on EPS
- ECFY2026 Q3 · November 12, 2026-5.6% EPS+0.7% move
- CBRSFY2026 Q3 · November 12, 2026-333.5% EPS-3.3% move
- BNFY2026 Q3 · November 12, 2026-6.1% EPS-1.0% move
- NUFY2026 Q3 · November 12, 2026-2.8% EPS-4.0% move
- PBRFY2026 Q3 · November 10, 2026-13.0% EPS-2.5% move
- EMBJFY2026 Q3 · November 10, 2026-49.4% EPS+7.0% move
Get the AVTR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-28T14:05:15.608732+00:00
- FN2 earnings calendar · 2026-10-29T01:23:20.584741+00:00
- Polygon adjusted daily market bars · 2026-10-29T03:40:43.174153+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-29T03:40:43.171270+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-29. For educational purposes only; not investment advice.